Setmelanotide Fails to Significantly Reduce BMI in Rare Obesity Forms | Endocrine Today

A drug aimed at treating obesity linked to rare genetic mutations has shown limited effectiveness in a recent trial, according to topline results released March 17, 2026. Setmelanotide, marketed as Imcivree by Rhythm Pharmaceuticals, did not induce significant reductions in body mass index (BMI) across four groups of patients with different genetic variants impacting appetite regulation. Even as some post-hoc analyses suggested benefit in specific subgroups, the overall findings underscore the complexity of genetic obesity and the challenges of developing targeted therapies.

Understanding the Genetic Basis of Obesity

Obesity is often viewed as a lifestyle-related condition, but a growing body of research highlights the role of genetics in a subset of cases. The EMANATE trial focused on individuals with heterozygous variants – meaning they have one altered copy – in four genes crucial for the melanocortin-4 receptor (MC4R) pathway. This pathway plays a vital role in signaling fullness and regulating energy balance. The genes studied were POMC/PCSK1, LEPR, SRC1, and SH2B1. Mutations in these genes can disrupt the MC4R pathway, leading to increased appetite and a predisposition to severe obesity, often beginning in early childhood. Setmelanotide received FDA approval in 2020 for some of these genetic deficiencies, but this latest trial expands the investigation into a broader range of mutations.

Trial Design and Key Findings

The EMANATE trial was a randomized, double-blind, placebo-controlled study. This means participants were randomly assigned to receive either setmelanotide or a placebo (an inactive substance) without knowing which they were getting, and neither the participants nor the researchers knew who was receiving what until the study concluded. This design minimizes bias. The trial involved four substudies, each focusing on one of the genetic variants. Participants received the study drug or placebo for one year.

The primary endpoint of the study was the change in BMI from baseline to one year. Unfortunately, none of the four substudies demonstrated a statistically significant reduction in BMI with setmelanotide compared to placebo. Specifically, the placebo-adjusted BMI changes were -4.3% for POMC/PCSK1, -3.6% for LEPR, -4.0% for SRC1, and -1.7% for SH2B1. This means the observed differences between the setmelanotide and placebo groups were not large enough to rule out the possibility of chance.

Post-Hoc Analyses Offer Nuance

While the primary endpoint wasn’t met, further analysis revealed some intriguing signals. Post-hoc analyses, which are conducted after the main study is complete, suggested potential benefit in patients with POMC/PCSK1 and SRC1 variants. Patients with a POMC/PCSK1 variant experienced a 5.5% greater decline in BMI with setmelanotide versus placebo (P = .001), and those with an SRC1 variant had a 6.2% greater BMI decrease (P < .0001). However, it’s crucial to remember that post-hoc analyses are exploratory and should be interpreted with caution. They can generate hypotheses for future research but are not definitive proof of efficacy.

Further analysis focusing on patients who completed the full year of treatment also showed more pronounced effects. Those with a POMC/PCSK1 variant had a 9.7% larger decline in BMI with setmelanotide (P = .0002), and those with an SRC1 variant had an 8% greater decrease (P = .0158). The difference between these results and the initial findings highlights the importance of considering adherence and completion rates in clinical trials.

Safety Profile Remains Consistent

The safety profile of setmelanotide in this trial was consistent with previous studies. The most commonly reported adverse events were skin hyperpigmentation (darkening of the skin), injection site reactions, nausea, vomiting, and headache. No new safety signals were identified, suggesting the drug remains generally well-tolerated.

Implications for Patients and Future Research

These findings are undoubtedly disappointing for patients and families hoping for a more effective treatment option for genetically-driven obesity. It’s important to remember that setmelanotide remains approved for specific genetic deficiencies, and this trial does not negate those approvals. However, it does suggest that the drug’s efficacy may be more limited than initially anticipated, and that identifying patients who are most likely to respond will be critical.

Rhythm Pharmaceuticals plans to continue analyzing the EMANATE data to refine its understanding of which genetic variants are most responsive to setmelanotide. The company is also developing next-generation MC4R agonists, which may offer improved efficacy and target a wider range of genetic mutations. According to a press release from Rhythm Pharmaceuticals, these future therapies will focus on identifying true loss-of-function variants, potentially leading to more personalized treatment approaches.

The Challenge of Genetic Obesity

This trial underscores the complexity of obesity, even in cases with a clear genetic component. The MC4R pathway is just one of many biological systems involved in appetite and weight regulation, and other genetic and environmental factors likely play a role. Developing effective therapies for genetic obesity will require a deeper understanding of these complex interactions and a more personalized approach to treatment.

The FDA continues to evaluate and expand approvals for setmelanotide based on genetic testing. Recent expansions in 2024 have included younger children, highlighting the ongoing effort to address this challenging condition.

What comes next involves continued research into the genetic underpinnings of obesity, refinement of diagnostic testing to accurately identify responsive patients, and the development of novel therapies targeting multiple pathways involved in energy balance. For individuals with suspected genetic obesity, consultation with a qualified medical geneticist and endocrinologist is essential.